PsyAccess introduces a registry-verified index of authorized ketamine- and psychedelic-assisted therapy providers operating across 27 European countries.
PsyAccess represents the patient-facing side of our belief in this field’s progress: built on credibility, not sensationalism.” — Iurii Filatov, Co-Founder & CEO, Pink Elephant GroupLISBON, PORTUGAL, September 17, 2026 /EINPresswire.com/ — Despite being a treatment category that frequently dominates headlines, licensed esketamine and ketamine therapy, active clinical trials, and sanctioned psychedelic-assisted treatments remain surprisingly difficult to locate throughout Europe. Details are fragmented across two dozen regulatory frameworks and numerous languages, promotional materials from clinics are mixed with factual information, and when someone consults an AI assistant for guidance, there exists no dependable reference for it to draw upon. PsyAccess, debuting today, serves as that reference: a complimentary listing of 487 licensed and registry-confirmed entries spanning 27 nations, with each entry featuring the originating source link displayed directly on the profile.
Inclusion confirms licensing and factual accuracy against governmental registries, never clinical excellence, effectiveness, or the therapy itself. PsyAccess refrains from ranking any providers.
The initial view of the map reveals how highly unequal access truly is. Among the 103 providers cleared to deliver psychedelic-assisted therapy in the strict sense, 101 are practitioners operating under Switzerland’s individual-patient authorization system, while the remaining 2 are German facilities engaged in a sanctioned psilocybin compassionate-use initiative (BfArM, §3 BtMG). All other nations in the directory show zero providers. Seven countries — Cyprus, Estonia, Latvia, Lithuania, Malta, Romania, and Slovakia — each show just a single confirmed provider of any type. “Legal” and “accessible,” it appears, carry vastly different connotations depending on a patient’s location.
What distinguishes this directory is not merely its existence, but its construction. In a sector where provider advertising often blurs with verified data, and US-influenced directories profit from paid placements, PsyAccess takes the near-opposite approach. Registration is complimentary, and no financial arrangement influences a provider’s inclusion, ranking, or verification process. Each entry demands a minimum of two separate sources, meeting the editorial standard for fact-checking, and in every case where a public registry exists, one of those sources must be that official registry. A submission that fails to satisfy this criterion is not quietly marked as “unconfirmed.” It is eliminated, remaining absent until it can be re-verified.
These treatment pathways are not equivalent, and the directory maintains clear distinctions: 212 authorized esketamine facilities, 129 clinical trial locations, 103 sanctioned psychedelic-assisted therapy providers, and 43 ketamine or ketamine-assisted psychotherapy practices. Regarding the 129 trial sites, involvement constitutes research under a controlled study, not a form of available medical treatment. Counting only the routes through which a patient can actually receive care, the map lists 358 providers, not 487.
“PsyAccess is the patient-facing component of our conviction that this field improves through accountability, not exaggeration. Every listing points back to a government registry, and anything we cannot substantiate, we remove rather than embellish. PsyAccess is a member of Pink Elephant Group, and it earns that confidence by functioning autonomously from our other operations.”
Iurii Filatov Co-Founder & CEO, Pink Elephant Group
“With growing interest in psychedelic medicine, patients are navigating an increasingly complicated environment involving approved treatments, off-label medical practice, and experimental options limited to research settings. Simply locating a practitioner online reveals little about the regulatory standing, scientific evidence, or safety measures associated with that care. Transparent, source-based systems that assist individuals in determining what is truly accessible — and that explicitly differentiate medical treatment from research involvement — represent a vital move toward safer, more informed, and more equitable access.”
Dr Rayyan Zafar PhD, MRSB, Neuropsychopharmacologist and UKRI Postdoctoral Fellow
“When someone is struggling and cannot identify a clear path forward, it becomes all too common to resort to unregulated alternatives out of urgency. Mental health care demands a solid foundation: a coordinated care team, a defined ethical code, and a secure setting. This is not about casting judgment. It is about acknowledging that assisting vulnerable individuals requires structure and collaborative expertise.”
Òscar Parés Founder and CEO, Clínica Synaptica
“The last decade has witnessed a dramatic rise in demand for psychedelic treatments, yet patients frequently lack guidance on where to locate options with strong clinical governance. PsyAccess is addressing that void. Featuring nearly 490 verified providers listed across Europe, this serves as an important tool for locating licensed clinics and research facilities. I anticipate the number of treatment centers will expand rapidly in the coming years as psychedelics gain approval, making a free, current directory increasingly valuable.”
Tom McDonald Board member and co-founder, Clerkenwell Health
“As a physician who administers ketamine treatments, patient safety and rigorous medical protocols are my foremost concerns. Too many individuals seeking psychedelic therapy in Europe end up in unregulated or unverified environments simply because they are unaware of alternatives. A platform like psyaccess.health offers a crucial medical screening function, linking patients with disciplined, professionally overseen care.”
Dr Christopher Gauci MD MRCS(Ed) EDAIC, Anaesthetist and intensive care specialist
PsyAccess is also exceptionally candid regarding what it does not do. It avoids ranking providers or singling out “top” clinics. It makes no assertions about treatment effectiveness. Coverage gaps in certain nations reflect actual access limitations, and where a country has two licensed facilities, the directory reflects exactly that. All of this information is clearly stated on the website, not hidden within fine print.
The directory is free to use, accessible in five languages (English, German, Spanish, French, and Polish), and retains no data from its browser-based eligibility assessment unless a user voluntarily submits an inquiry. The complete dataset is openly published under CC BY at psyaccess.health/data. Any provider may request corrections or removal of its own entry at psyaccess.health/for-providers. The service is operational now at psyaccess.health, with the complete verification process publicly available at psyaccess.health/methodology.
About PsyAccess
PsyAccess is a free, registry-confirmed directory of authorized esketamine and ketamine treatment, clinical trial sites, and sanctioned psychedelic-assisted therapy across 27 European countries. Each entry traces to an official source, displays a last-verified date, and undergoes re-assessment on a fixed 90-day cycle. Inclusion confirms licensing and factual accuracy against governmental registries, never clinical excellence, effectiveness, or the therapy itself. Providers incur no fees for listing, and no payment impacts inclusion, ranking, or verification. PsyAccess is a member of Pink Elephant Group and operates autonomously within it.
psyaccess.health
Anna Maximova
Pink Elephant Group
a.maximova@pink-elephant.co
Visit us on social media:
LinkedIn
X
Other
